HeXun Biosciences Co Ltd (6986) AI Stock Analysis

HeXun Biosciences Co Ltd

(TPEx:6986)

Select Model

Rating:73Outperform

Price Target:TWD 45.00▲(20.00% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong financial performance is the primary support, driven by a solid balance sheet, high margins and positive cash generation. However, declining revenue and free cash flow weaken the outlook, while the share price remains below all listed moving averages with negative MACD. Moderate valuation provides some support, producing an overall score of 73.

Positive Factors

Low LeverageVery low leverage gives the company substantial financial flexibility and limits interest-related pressure on earnings. A sizable equity base also improves resilience during biotechnology earnings volatility, allowing management to fund operations and pursue opportunities without depending heavily on borrowing.

Negative Factors

Revenue ContractionThe sharp 2025 revenue decline indicates that recent earnings strength is not yet supported by consistent top-line expansion. Continued contraction would reduce operating leverage, limit resources available for reinvestment, and make future profitability more dependent on cost control or episodic revenue.

HeXun Biosciences Co Ltd (6986) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.96B
Dividend Yield: 0.52%
Average Volume (3M): 67.37K
Price to Earnings (P/E): 15.6
Beta (1Y): 0.25
Revenue Growth: ―
EPS Growth: ―
Country: TW
Employees: 53
Sector: General
Sector Strength: 55
Industry: Biotechnology

HeXun Biosciences Co Ltd Business Overview & Revenue Model

Company Description

HeXun Biosciences Co., Ltd., a Taiwanese enterprise, focuses on the research, development, and application of stem cell technologies and treatments. The company also offers a comprehensive suite of related services, including contract development and...

HeXun Biosciences Co Ltd Financial Statement Overview

Summary

Strong overall financial health, supported by high profitability, very low debt, rising equity and assets, and substantial operating and free cash flow. The score is tempered by the 18.8% revenue decline, weaker margins and net income, and a 37.8% decrease in free cash flow.

Income Statement

78Positive

Balance Sheet

91Very Positive

Cash Flow

84Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	308.21M	130.57M	293.23M	286.42M	49.47M	0
Gross Profit	263.83M	113.73M	245.15M	260.67M	44.61M	0
EBITDA	164.03M	55.64M	146.95M	187.36M	11.17M	-29.51M
Net Income	116.33M	33.49M	111.91M	147.22M	-5.19M	-42.99M
Balance Sheet
Total Assets	1.18B	571.43M	837.07M	706.92M	404.15M	294.62M
Cash, Cash Equivalents and Short-Term Investments	828.93M	329.67M	509.63M	372.99M	191.74M	85.03M
Total Debt	34.66M	70.06M	36.58M	35.02M	69.42M	74.10M
Total Liabilities	109.95M	98.07M	95.47M	86.34M	89.28M	79.86M
Stockholders Equity	1.07B	473.36M	741.60M	620.58M	314.87M	214.75M
Cash Flow
Free Cash Flow	133.02M	20.28M	135.04M	83.63M	10.00M	-35.50M
Operating Cash Flow	163.75M	43.09M	163.89M	120.92M	11.23M	-35.50M
Investing Cash Flow	-209.38M	-25.28M	-158.38M	-137.29M	-79.05M	-26.95M
Financing Cash Flow	264.50M	120.12M	1.69M	-40.30M	102.54M	75.79M

HeXun Biosciences Co Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6986 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6986	73Outperform	TWD 1.96B	15.55	―	0.52%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

TW:6986 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6986	HeXun Biosciences Co Ltd	37.50	-21.83	-36.79%
TW:6704	Gwo Xi Stem Cell Applied Technology Co., Ltd.	20.20	-6.05	-23.05%
TW:6808	3D Global Biotech Inc.	26.10	-18.35	-41.29%
TW:6932	Merdury Biopharmaceutical Corporation	5.23	-4.87	-48.22%
TW:6973	U-Neuron Biomedical Inc	54.89	13.96	34.12%
TW:7731	MARX Biotech Co., Ltd.	4.26	-0.95	-18.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

HeXun Biosciences Co Ltd AI Stock Analysis